Patients and procedures
RETINAL DISEASE
Treatment-naïve patients with a diagnosis of nAMD in the study eye and for whom the decision to treat with IVT-AFL had been made were eligible for inclusion. Patients must have received their first IVT-AFL treatment between January 1, 2014, and April 30, 2015. Patients were excluded if they had another retinal disease, did not meet the local indication criteria, or were participating in an interventional study. All decisions regarding treatment, diagnosis, and follow-up were at the discretion of the attending physician according to local medical practice. Patients were treated with the option of a reactive approach (pro re nata) or an individualized proactive approach (treat-and-extend [T&E]), in accordance with the European Medicines Agency Summary of Product Characteristics for IVT-AFL [In patients with both eyes treated but with different treatment start dates for each eye, the first eye to be treated was retained as the study eye. In patients with both eyes treated during the initial visit, the eye with the worst BCVA at baseline was retained as the study eye in the full analysis set (FAS); where the BCVA was similar between both eyes at baseline, the right eye was selected as the study eye by convention. Therefore, patients with both eyes treated were included only once in the FAS. For the safety analysis, both treated eyes (where applicable) were retained in the safety analysis set (SAS).